DETERMINATION: Phase III Trial of VRd ± ASCT With Ongoing Lenalidomide Maintenance in Patients With NDMM

June 3-7, 2022; Chicago, Illinois
In the phase III DETERMINATION trial, addition of ASCT to VRd induction with ongoing lenalidomide maintenance resulted in prolonged median PFS—but not OS—in newly diagnosed multiple myeloma.
Format: Microsoft PowerPoint (.ppt)
File Size: 300 KB
Released: June 10, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation
Seattle Genetics

Related Content

Experts answer pressing audience questions from a live satellite symposium on the management of relapsed/refractory multiple myeloma, from Clinical Care Options (CCO)

Paul G. Richardson, MD
Program Director
Natalie S. Callander, MD Noopur Raje, MD
Released: August 18, 2022

Expert text module that provides insights from a leading patient advocate/healthcare professional on best practices in education for patients with CLL, from Clinical Care Options (CCO)

Nichole Fisher Headshot Nichole Fisher, RN, BSN Brian Koffman, MDCM (retired), MS Ed Anthony Perissinotti, PharmD, BCOP Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: August 17, 2022 Expired: August 16, 2023

Comentario experto de los datos de la EHA 2022 sobre inhibidores de la QBT para LLC y LCM de Clinical Care Options (CCO)

Othman Al-Sawaf, MD Lydia Scarfò, MD Released: August 15, 2022

Expertengespräch über die Daten der EHA 2022 zu BTK-Inhibitoren für CLL und MCL, von Clinical Care Options (CCO)

Othman Al-Sawaf, MD Lydia Scarfò, MD Released: August 15, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings